Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mixed lineage kinase 1 (MLK1) is a serine/threonine kinase and a member of the mixed lineage kinases (MLKs), which are part of the mitogen-activated protein kinase kinase kinase (MAP3K) family. MLK1 acts upstream in MAP kinase signaling pathways, particularly influencing cellular processes such as cell migration, invasion, cell cycle regulation, and apoptosis. It is implicated in neurodegenerative diseases like Parkinson’s and Alzheimer’s, as well as cancer. Small molecule inhibitors like CEP-1347 and CEP-11004 target the MLK family, demonstrating neuroprotective effects.
ATP competitive inhibitor of MLK family kinases
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mixed Lineage Kinase 1 (MLK1).